Limited Asian Fallout From Pfizer-Allergan Merger?
This article was originally published in Scrip
Executive Summary
As far as Asian and emerging pharma markets go, it is clear that Pfizer Inc. will be the dominant partner in the planned $160bn merger with Allergan PLC. The US firm has a broad reach in these areas that Allergan will be looking to tap into, and major restructuring in big regional markets such as China and Japan looks unlikely.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.